Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?

被引：2
|
作者：
Fabi, A [1 ]
Ferretti, G [1 ]
Salesi, N [1 ]
Papaldo, P [1 ]
Carlini, P [1 ]
Ciccarese, M [1 ]
Di Cocco, B [1 ]
Cecere, F [1 ]
Nardoni, C [1 ]
Felici, A [1 ]
Cognetti, F [1 ]
机构：
[1] Regina Elena Inst Canc Res, Div Med Oncol A, I-00144 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷 / 03期
关键词：
D O I：
10.1093/annonc/mdi078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [31] Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
    Jehn, Christian F.
    Hemmati, Philipp
    Lehenbauer-Dehm, Silvia
    Kuemmel, Sherko
    Flath, Bernd
    Schmid, Peter
    CLINICAL BREAST CANCER, 2016, 16 (06) : 514 - 519
  • [32] Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
    Irvin, William J., Jr.
    Orlowski, Robert Z.
    Chiu, Wing-Keung
    Carey, Lisa A.
    Collichio, Frances A.
    Bernard, Philip S.
    Stijleman, Inge J.
    Perou, Charles
    Ivanova, Anastasia
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2010, 10 (06) : 465 - 470
  • [33] Diagnosis of HER2 protein overexpression in patients with breast cancer in Brazil
    Muranaka, A. H.
    VALUE IN HEALTH, 2008, 11 (03) : A54 - A54
  • [34] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND GEMCITABINE (G) COMBINATION IN METASTATIC BREAST CANCER (MBC) PATIENTS: ACTIVITY AND TOXICITY
    Fabi, A.
    Papaldo, P.
    Ciccarese, M.
    Salesi, N.
    Lorusso, V.
    Ferretti, G.
    Di Cocco, B.
    Carlini, P.
    Cecere, F.
    Pellicciotta, M.
    Morace, N.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [35] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [36] NON PEGYLATED LIPOSOMAL DOXORUBICIN BEYOND THE FIRST LINE TREATMENT OF METASTATIC BREAST CANCER PATIENTS: A RETROSPECTIVE ANALYSIS
    Bernhard, S.
    Mansi, L.
    Nerich, V.
    Villanueva, C. B.
    Dobi, E.
    Almotlak, H.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Pivot, X.
    ANNALS OF ONCOLOGY, 2012, 23 : 128 - 129
  • [37] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [38] Liposomal doxorubicin in combination with trastuzumab and docetaxel as first line chemotherapy in HER-2 metastatic breast cancer patients
    Bighin, C.
    Puglisi, F.
    Cavazzini, G.
    Olmeo, N.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Labianca, R.
    Crino, L.
    Simoncini, E.
    Manzione, L.
    Nardi, M.
    Cortesi, E.
    Venturini, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 9 - 9
  • [39] Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: A valuable therapeutic option requiring caution
    Bernardi, Daniele
    Errante, Domenico
    Stefani, Micaela
    Salvagno, Luigi
    BREAST, 2010, 19 (06): : 549 - 550
  • [40] Pegylated liposomal doxorubicin in previously treated patients with metastatic breast cancer - a large multicenter phase II trial
    Al-Batran, SE
    Bischoff, J
    von Minckwitz, G
    Atmaca, A
    Kleeberg, U
    Meuthen, I
    Morack, G
    Lerbs, W
    Hccker, D
    Jager, E
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
12345